# A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants

> **NCT04475848** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 88 (actual)

## Conditions studied

- Autistic Disorder
- Autism Spectrum Disorder
- Child Development Disorders, Pervasive
- Mental Disorders
- Neurodevelopmental Disorders

## Interventions

- **DRUG:** RO6953958
- **DRUG:** Placebo
- **DRUG:** Midazolam

## Key facts

- **NCT ID:** NCT04475848
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-15
- **Primary completion:** 2022-02-06
- **Final completion:** 2022-02-06
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2024-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04475848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04475848, "A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04475848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*